http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
-
Ehave Releases Additional Information On Partnership With Cutting Edge Data Provider As It Expands Capabilities
-
Ehave Hires Institutional Review Board (IRB) As It Solidifies Partnership With Tristar Wellness Launching Ketamine Clinical Trials In Miami
-
Dr. Jeffrey Kamlet Internationally Recognized Expert on Cardiac Safety in Ibogaine Treatment Joins Ehave as Chief Medical Officer
-
Ehave KetaDASH Subsidiary Commences Data Collection for Potential Patients and Partnering Clinics
-
Ehave, Inc. Announces Engagement of Legal Counsel to Advise on Launch of KetaDASH in Miami Metro Area and across United States; Ehave Creates Path to Revenue Stream
-
Ehave Prepares to Launch Ketamine Clinical Trials Using Brain Scientific’s Brain Mapping Technology
-
Ehave CEO Benjamin Kaplan to be Featured on Psychedelic Spotlight Segment of New to the Street Airing on NewsMax on Sunday March 14th at 10:00 AM EST and Fox Business March 15th at 7:30 PM EST
-
Ehave Inc. Files for KetaDash Trademark and to Uplist its Shares to the OTCQB
-
Ehave Inc. Reaches Milestone; Ketamine IV Therapy Provider KetaDASH to Launch Beta in Second Quarter 2021
-
Psychedelic Partnership Reached, Ehave Inc. and Brain Scientific Sign Memorandum of Understanding to Map Brain Response to Psychedelic Treatment, Collaborate in the Development of Neural Net Algorithm
-
Ehave Couples KetaDASH with Digital Therapeutics Expertise to Combat Clinical Depression
-
Ehave Looks to Expand KetaDASH to Palliative Care
-
Ehave, Inc. Utilizes Artificial Intelligence and Machine Learning for Big Data Management in Mental Healthcare
-
Ehave Closes Transaction to Acquire CureDash Assets, Adds KetaDASH Home Delivery Service for Ketamine Clinics
-
Ehave Revolutionizes Patient Medical Records for Psychedelic Mental Health
-
Ehave, Inc. Closes 20/20 Global Transaction, Mycotopia Therapy Now Operating as a Publicly Traded Company with Intent to Focus on Psychedelic Sector
-
Ehave Forms Partnership with Cognitive Apps to Introduce Revolutionary AI Voice Assistant That Will Revolutionize Mental Health in Psychedelic Sector
-
Ehave, Inc. names Patrick Gallagher Director of Sales and Customer Acquisition
-
Ehave, Inc. Partners with Cognitive Apps to Add Artificial Intelligence-Powered Mental Health Analytical Platform for Psychedelic Use in G20 Countries
-
Ehave, Inc. Files to List on the Canadian Stock Exchange and Applies to Upgrade to OTCQB Exchange
-
Ehave, Inc. Announces Repositioning of Mycotopia Therapies to Maximize Shareholder Value
-
Ehave KetaDASH Subsidiary Announces Intent to Battle Major Depression through Home Delivery of Ketamine
-
Ehave, Inc. Issues CEO Letter to Stockholders, Reports on Significant Progress and Outlook for 2021
-
Ehave, Inc. Announces KetaDASH for Ketamine Home Delivery and Purchase of Curedash Assets